Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting

NEW YORK, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced today that three of its scientific abstracts have been accepted for presentation at the 2015 American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting to be held November 7-11, 2015, in San Francisco, CA.

The abstract and presentation details are as follows:

"Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)."
Authors:Harvey Moldofsky, R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Benjamin Vaughn, Bruce Daugherty, Amy Forst, Gregory Sullivan and Seth Lederman
Date & Time:Tuesday, November 10, 2015, 9:00 – 11:00 am
Location:ACR Poster Session C
"Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)."
Authors:R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Bruce Daugherty and Seth Lederman
Date & Time:Tuesday, November 10, 2015, 9:00 – 11:00 am
Location:ACR Poster Session C
"Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study."
Authors:Seth Lederman, R Michael Gendreau, Daniel J. Clauw, Lesley M. Arnold, Judith Gendreau, Bruce Daugherty and Amy Forst
Date & Time:Tuesday, November 10, 2015, 9:00 – 11:00 am
Location:ACR Poster Session C

About Tonix Pharmaceuticals Holding Corp.

Tonix is dedicated to the invention and development of novel pharmaceutical products for medical conditions that it believes have broad societal impact, that are not well served by currently available therapies and that represent large potential commercial opportunities. Tonix's Tonmya™ is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. This press release and further information about Tonix can be found at

Tonmya™, TNX-102 SL and TNX-201 are Investigational New Drugs and have not been approved for any indications.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2014 and Quarterly Report on Form 10-Q for the period ended June 30, 2015, as filed with the Securities and Exchange Commission (the "SEC") on February 27, 2015 and August 7, 2015, respectively, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

CONTACT: Leland Gershell
         Chief Financial Officer
         (212) 980-9155 x104
         Jenene Thomas Communications (investors)
         Jenene Thomas
         (908) 938-1475
         Dian Griesel Int'l. (media)
         Susan Forman / Laura Radocaj
         (212) 825-3210